Aljead, M.; Qashta, A.; Jalal, Z.; Jones, A.M.
Metabolic and Endocrine ADRs of Atypical Antipsychotics (AAPs) in Paediatric Patients with Autism Spectrum Disorder (ASD): A Review of Prevalence, Risk Factors, and Implications for Clinical Monitoring. J. Clin. Med. 2025, 14, 7942.
https://doi.org/10.3390/jcm14227942
AMA Style
Aljead M, Qashta A, Jalal Z, Jones AM.
Metabolic and Endocrine ADRs of Atypical Antipsychotics (AAPs) in Paediatric Patients with Autism Spectrum Disorder (ASD): A Review of Prevalence, Risk Factors, and Implications for Clinical Monitoring. Journal of Clinical Medicine. 2025; 14(22):7942.
https://doi.org/10.3390/jcm14227942
Chicago/Turabian Style
Aljead, Mashal, Aya Qashta, Zahraa Jalal, and Alan M. Jones.
2025. "Metabolic and Endocrine ADRs of Atypical Antipsychotics (AAPs) in Paediatric Patients with Autism Spectrum Disorder (ASD): A Review of Prevalence, Risk Factors, and Implications for Clinical Monitoring" Journal of Clinical Medicine 14, no. 22: 7942.
https://doi.org/10.3390/jcm14227942
APA Style
Aljead, M., Qashta, A., Jalal, Z., & Jones, A. M.
(2025). Metabolic and Endocrine ADRs of Atypical Antipsychotics (AAPs) in Paediatric Patients with Autism Spectrum Disorder (ASD): A Review of Prevalence, Risk Factors, and Implications for Clinical Monitoring. Journal of Clinical Medicine, 14(22), 7942.
https://doi.org/10.3390/jcm14227942